RDIF Approves Sputnik V Russian Vaccine Production In India

Russian approved Sputnik V vaccine for the Novel Coronavirus infection to be produced in India. 

The Russian Direct Investment Fund (RDIF) and Hetero, one of India’s generic pharmaceutical companies approved to produce Sputnik V, in India.

Nearly 100 million doses per year of Sputnik V COVID-19 would be produced in India.

The companies along with the RDIF decided to start the production of Sputnik V at the beginning of 2021.

Murali Krishna Reddy, the Director of International Marketing of Hetero Labs Limited said, “We are pleased to collaborate with RDIF as a manufacturing partner for the most anticipated Sputnik V vaccine for the treatment of COVID-19.” He further added, “This collaboration is another step towards our commitment in the battle against Covid-19 and realizing the objective of ‘Make in India’ campaign as envisioned by our Prime Minister of India.”

According to the RDIF, Russia’s sovereign wealth fund, the vaccine’s interim clinical trial results show 95 % efficacy on the 42nd day after the first dose. Potential vaccine of the Novel Coronavirus Sputnik V is currently in the third phase of the clinical trials.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, released a statement and said, “We are delighted to announce the agreement between RDIF and Hetero that will pave the way to the production of the safe and highly effective Sputnik V vaccine on Indian soil.” Kirill Dmitriev further added, “Thanks to our cooperation with Hetero, we will be able to significantly increase production capacity and provide people of India with an efficient solution in this challenging period of the pandemic.”

Stay tuned for further updates.


Please enter your comment!
Please enter your name here